(88 days)
BioSign™ is an accessory to a multi-parameter patient monitor (bedside or ambulatory) or clinical information system and is indicated for use by health care professionals with those non-pediatric high dependency care patients for whom multi-parameter patient monitoring has been routine.
BioSign™ provides the clinician with a trend graph of the patient status index based on a weighted average of five vital signs namely heart rate, respiration rate, temperature, oxygen saturation and blood pressure. The patient status index is a single measure of the patient's condition and represents how different the patient's vital signs are with respect to normality. BioSign™ is an adjunct to and is not intended to replace vital signs monitoring.
BioSign™ is a software accessory to standard multiple parameter physiological patient monitors (bedside or ambulatory) or clinical information systems. It operates on a standard medical grade computer.
BioSign™ is a software device embedded in a standard medical grade computer that through advanced signal processing can combine physiological signals in order to produce a single graph representation of patient condition.
BioSign™ is a computerized analysis system that can accept multiple channels of physiological data (for example heart rate, respiratory rate, temple viauncis of pressure and oxygen saturation as inputs). Through advanced signal procession, BioSign can identify changes in patient status.
The provided document describes the BioSign™ device, its indications for use, and its substantial equivalence to other devices. However, the document does not contain specific acceptance criteria, detailed study designs, or performance metrics from a formal clinical study that would allow for a comprehensive description of acceptance criteria and how a study proves the device meets those criteria.
The document mentions "Design verification" and "Design validation" but only provides generic statements about their conclusions. It does not provide the quantitative performance criteria or the results of studies against those criteria.
Therefore, many of the requested details cannot be extracted from the provided text.
Here's an analysis of what can be extracted and what information is missing:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (Hypothetical, as not explicitly stated in document) | Reported Device Performance |
|---|---|
| Device Specifications Conform to User Needs and Intended Use (Inferred from "Design validation") | "Design validation testing of the BioSign™ patient status index model has been conducted and concluded that device specifications conforms with user needs and intended use." |
| Hardware and Software Meet Specified Requirements (Inferred from "Design verification") | "Design verification testing of the BioSign™ hardware and software against the specified requirements has been conducted and the BioSign™ device has been found to meet the specifications." |
| Electrical Safety Compliance | "BioSign™ systems comply with BS EN 60601-1-1:2001, 'Safety requirements for medical electrical systems.'" |
| Accuracy/Reliability of Patient Status Index (Missing) | Not specified or quantified. The document states it produces a "single graph representation of patient condition" and identifies "changes in patient status" but doesn't quantify its accuracy or performance in doing so. |
| Sensitivity/Specificity in Identifying Status Changes (Missing) | Not specified or quantified. |
| User Interface Usability/Effectiveness (Missing) | Not specified. |
Missing Information in the Document: The document does not provide specific acceptance criteria in terms of quantitative performance metrics (e.g., accuracy, precision, sensitivity, specificity, agreement with a gold standard) for the BioSign™ patient status index. It only states that design validation and verification were performed and concluded positively.
2. Sample size used for the test set and the data provenance
- Sample Size for Test Set: Not specified.
- Data Provenance (e.g., country of origin, retrospective/prospective): Not specified. The document vaguely refers to "historic clinical data" in the context of substantial equivalence to another device (Sonicaid System 8002) but does not link this directly to the BioSign™ device's own performance testing.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- Number of Experts: Not specified.
- Qualifications of Experts: Not specified.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
- Adjudication Method: Not specified.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- The document does not describe an MRMC comparative effectiveness study where human readers' performance with and without AI assistance was evaluated. The BioSign™ is described as "decision support" and an "adjunct," but no study is detailed to quantify its assistance to clinicians.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- The document mentions "Design validation testing of the BioSign™ patient status index model has been conducted..." which implies an evaluation of the algorithm's performance. However, no specific metrics or study details for this standalone performance are provided. It states the system "can identify changes in patient status" and produces an "index and associated trend graph indicative of the patient's state," but without quantification.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- Type of Ground Truth: Not explicitly stated for performance testing. The description of how the BioSign™ model is derived (similar to Sonicaid System 8002) references "a model derived from historic clinical data" and "examination of historical clinical data." This suggests that a form of historical clinical data was used as a basis for establishing "normality" for the patient status index, which could imply expert-defined normal ranges or outcomes from those historical cases. However, no specific ground truth methodology for its own validation study is detailed.
8. The sample size for the training set
- Sample Size for Training Set: Not specified. The document refers to a "model derived from historic clinical data" but does not provide details on the size or characteristics of this data.
9. How the ground truth for the training set was established
- How Ground Truth was Established: Not explicitly detailed. The statement "provides decision support to a clinician in the determination of normality based on a model derived from historic clinical data" (in comparison to Sonicaid System 8002 which had criteria established by "examination of historical clinical data") suggests that the "normality" concept for the patient status index was established through analysis of historical physiological data and likely included clinical interpretation or consensus within that historical dataset. No specific methodology (e.g., expert review, outcome correlation for each case) is provided.
{0}------------------------------------------------
JAN 3 1 2006
1. General Information
| Trade Name of Device: | “BioSign™” |
|---|---|
| Common/Usual Name: | Accessory to multi-parameter patientmonitor (bedside or ambulatory) |
| Classification Name: | Monitor, physiological, patient |
| Submitters Name and Address: | Oxford BioSignals LtdMagdalen CentreOxford Science ParkOxfordOX4 4GAUnited KingdomTel +44 (0) 1865 336170Fax +44 (0) 1865 336180 |
| Manufacturer: | Oxford BioSignals LtdMagdalen CentreOxford Science ParkOxford |
2. Device Description
BioSign™ is a software accessory to standard multiple parameter physiological patient monitors (bedside or ambulatory) or clinical information systems. It operates on a standard medical grade computer.
OX4 4GA
United Kingdom
BioSign™ is a software device embedded in a standard medical grade computer that through advanced signal processing can combine physiological signals in order to produce a single graph representation of patient condition.
BioSign™ is a computerized analysis system that can accept multiple channels of physiological data (for example heart rate, respiratory rate, temple viauncis of pressure and oxygen saturation as inputs). Through advanced signal procession, BioSign can identify changes in patient status.
{1}------------------------------------------------
3. Indications for Use
KO53112 2/3 Ilcations for Use
BioSign™ is an accessory to a multi-parameter patient monitor (bedside or ambulatory) or clinical information system and is indicated for use by health care professionals with those non-pediatric high dependency care patients for whom multiparameter patient monitoring has been routine.
. .
BioSign™ provides the clinician with a trend graph of the patient status index based on a weighted average of five vital signs namely heart rate, respiration rate, temperature, oxygen saturation and blood pressure. The patient status index is a single measure of the patient's condition and represents how different the patient's vital signs are with respect to normality. BioSign™ is an adjunct to and is not intended to replace vital signs monitoring.
4. Substantial Equivalence
The BioSign™ device is substantially equivalent to the following devices:
Propaq 200 Series Monitors (K012451) multi-parameter physiological patient monitors. BioSign™ is a software accessory to multi-parameter physiological patient monitors and as such is substantially equivalent to the Propaq 200.
BioSign™ is an adjunct to a patient monitor and displays real time monitoring of heart rate, respiration rate, blood pressure, temperature and oxygen saturation and, therefore, the BioSign™ display is substantially equivalent to the Propag 200 series display, which provides real time monitoring of each physiological channel.
BioSign™ additionally provides a real time trend display of the data fusion of these vital signs.
Sonicaid System 8002 (K992607) is a software accessory for the computerized analysis of antepartum cardiotocograms (CTGs). It informs the clinician whether a CTG meets a number of criteria that are indicative of a normal CTG .These criteria were established by examination of historical clinical data.
BioSign™ is substantially equivalent to Sonicaid System 8002 in that its displayed graphical representation of the fused vital signs is created by computer analysis and provides decision support to a clinician in the determination of normality based on a model derived from historic clinical data.
A-2000 EEG Monitor with BIS (K030267) is an EEG monitoring system that monitors the state of the brain of an anesthetized or sedated patient. Raw EEG information obtained from patient sensors is processed with the complex Bispectral Index (BIS) algorithm and a number between 1 and 100 calculated and displayed to the clinician. This BIS index and associated trend graph provides a direct indication of the patient's level of anesthesia.
{2}------------------------------------------------
K053112 3/3 BioSign™ is substantially equivalent to the A-2000 EEG Monitor with BIS in that it also takes a patient's physiological signals and processes them in order to provide the clinician with an index and associated trend graph indicative of the patient's state.
5. Performance Studies
Design verification: Design verification testing of the BioSign™ hardware and software against the specified requirements has been conducted and the BioSign™ device has been found to meet the specifications.
Design validation: Design validation testing of the BioSign™ patient status index model has been conducted and concluded that device specifications conforms invith user needs and intended use.
Electrical Safety: BioSign™ systems comply with BS EN 60601-1-1:2001, "Safety requirements for medical electrical systems."
6. Conclusion
Based upon the indications for use and performance studies BioSign™ has been shown to be substantially equivalent for its intended use.
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the seal of the Department of Health and Human Services (HHS). The seal features a stylized eagle with three lines representing its body and wings. The words "DEPARTMENT OF HEALTH AND HUMAN SERVICES, USA" are arranged in a circular pattern around the eagle.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN 3 1 2006
Oxford BioSignals Limited c/o Mr. Howard M. Holstein Regulatory Counsel Hogan & Hartson, LLP 555 13m 24 NW Washington DC 20004
Re: K053112
Trade/Device Name: BioSignTM Regulation Number: 21 CFR 870.2300 Regulation Name: Physiological Patient Monitor (without arrhythmia detection or alarms) Regulatory Class: Class II Product Code: MWI Dated: November 4, 2005 Received: November 4, 2005
Dear Mr. Holstein:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have deterniined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
{4}------------------------------------------------
Page 2 - Mr. Howard M. Holstein
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Bhimmon for
Bram B. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
SECTION 4
INDICATIONS FOR USE
510(k) Number (if known): K05 3112
Device Name: BioSign™
Indications For Use:
BioSign™ is an accessory to a multi-parameter patient monitor (bedside or ambulatory) or clinical information system and is indicated for use by health care professionals with those nonpediatric high dependency care patients for whom multi-parameter patient monitoring has been routine.
BioSign™ provides the clinician with a trend graph of the patient status index based on a weighted average of five vital signs namely heart rate, respiration rate, temperature, oxygen saturation and blood pressure. The patient status index 140 is a single measure of the patient's condition and represents how different the patient's vital signs are with respect to normality. BioSign™ is an adjunct to and is not intended to replace vital signs monitoring
Warning: Federal (USA) law restricts this device to sale by or on the order of a physician
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
B. tummana
Division Sign Off
Page 1 of 1
Division Sign-Off
Division of Cardiovascular Devices
510(k) Number K053112
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).